Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA declines to approve Nabriva’s antibiotic for urinary tract infections

The U.S. Food and Drug Administration declined to approve Nabriva Therapeutics Plc’s antibiotic for complicated urinary tract infections, even as the United States grapples with the growing problem of antibiotic resistance.

Read More »

Eli Lilly Sells Two Legacy Drugs and Manufacturing Facility for $375 Million

Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.

Read More »

Big Pharma accused of ‘endless talk, no action’ on antibiotic threat

The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK government adviser said.

Read More »

Bacteriophages to the Rescue: A Possible Approach to Antibiotic Resistance

A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.

Read More »

NYU and Janssen Develop New Class of Proteins to Fight Antibiotic-Resistant Infections

Researchers at New York University School of Medicine and Janssen Research & Development, a Johnson & Johnson company, developed a new class of engineered proteins that may help fight the bacteria that cause Staph infections.

Read More »

Pfizer to shut two manufacturing plants in India

U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.

Read More »

RedHill’s antibiotic succeeds in late-stage study

RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Read More »

FDA Approves Aemcolo For Travelers’ Diarrhea

The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.

Read More »

WHO uncovers big national variations in antibiotics consumption

Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.

Read More »

Foamix’s treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom